Recombinant multivalent HFMD vaccine - Beijing Health Guard Biotechnology
Alternative Names: Recombinant multivalent enterovirus A and coxsackievirus vaccine - Beijing Health Guard BiotechnologyLatest Information Update: 20 Feb 2024
At a glance
- Originator Beijing Health Guard Biotechnology
- Class Enterovirus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Coxsackievirus infections; Enterovirus A infections
Most Recent Events
- 08 Feb 2024 Beijing Health Guard Biotechnology plans to submit an IND application for Coxsackievirus infections and Enterovirus A infections (Prevention) after 2025 (Beijing Health Guard Biotechnology pipeline, February 2024)
- 08 Feb 2024 Beijing Health Guard Biotechnology plans a clinical trial for Coxsackievirus infections and Enterovirus A infections (Prevention) (Parenteral) (Beijing Health Guard Biotechnology pipeline, February 2024)
- 06 Jan 2023 Research in Coxsackievirus infections (Prevention) in China (Parenteral), prior to January 2023 (Beijing Health Guard Biotechnology pipeline, January 2023)